Analgesic activity of the low molecular weight neurotrophin-3 dipeptide mimetic GTS-301
- Authors: Kolik L.G.1, Konstantinopolsky M.A.1, Sazonova N.M.1, Durnev A.D.1, Gudasheva T.A.1
-
Affiliations:
- FSBSI “Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies”
- Issue: Vol 520, No 1 (2025)
- Pages: 100-103
- Section: Articles
- URL: https://cijournal.ru/2686-7389/article/view/682051
- DOI: https://doi.org/10.31857/S2686738925010166
- EDN: https://elibrary.ru/tcgjna
- ID: 682051
Cite item
Abstract
It was previously shown that the original dipeptide mimetic of the 4th loop neurotrophin-3 (NT-3) hexamethylenediamide bis-(N-monosuccinyl-L-asparaginyl-L-asparagine) (GTS-301), like full-size neurotrophin, predominantly activates the tyrosine kinase receptor TrkC and has a neuroprotective effect in vitro at concentrations of 10-5-10-12 M, as well as after systemic administration on rodents – antidiabetic (0.1 and 0.5 mg/kg) and antidepressant (5 and 10 mg/kg) effects. In this work, the analgesic properties of GTS-301 were identified, which were manifested in the dose range of 0.01-10 mg/kg after acute intraperitoneal injection to rats in the “tail flick” test. Dipeptide GTS-301 increased the threshold of pain response by 20-30% and the effect persisted for at least 24 hours after administration.
Full Text

About the authors
L. G. Kolik
FSBSI “Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies”
Author for correspondence.
Email: kolik_lg@academpharm.ru
Russian Federation, Moscow
M. A. Konstantinopolsky
FSBSI “Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies”
Email: kolik_lg@academpharm.ru
Russian Federation, Moscow
N. M. Sazonova
FSBSI “Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies”
Email: kolik_lg@academpharm.ru
Russian Federation, Moscow
A. D. Durnev
FSBSI “Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies”
Email: kolik_lg@academpharm.ru
Сorresponding Мember of the RAS
Russian Federation, MoscowT. A. Gudasheva
FSBSI “Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies”
Email: kolik_lg@academpharm.ru
Сorresponding Мember of the RAS
Russian Federation, MoscowReferences
- Hohn A., Leibrock J., Bailey K., et al. // Nature. 1990. V. 344. P. 339–341.
- Rosenthal A., Goeddel D.V., Nguyen T., et al. // Neuron. 1990. V. 4. P. 767–773.
- Siuciak J. A., Altar A., Wiegand S. J., et al. // Brain Res. 1994. V. 633, № 1–2. P. 326–330.
- Malcangio M., Garrett N. E., Cruwys S., et al. // J. Neurosci. 1997. V. 17. № 21. P. 8459.
- Watanabe M., Endo Y., Kimoto K., et al. // Neurosci. Lett. 2000. V. 1–2. № 282. P. 61–64.
- Wilson-Gerwing T.D., Dmyterko M.V., Zochodne D.W., et al. // J. Neurosci. 2005. V. 25. № 3. P. 758–767.
- Gudasheva T.A., Povarnina P.Y., Tarasiuk A.V., et al. // Med Res Rev. 2021. V. 41. № 5. P. 2746-2774. doi: 10.1002/med.21721.
- Гудашева Т.А., Сазонова Н.М., Тарасюк А.В., и др. // ДАН. 2022. Т. 505. № 1. С. 303-309.
- Ягубова С.С., Чернышевская М.А., Островская Р.У., и др. // ДАН. 2023. Т. 512.
- Hardy J.D., Wolff H.G. and Goodell H. // J Clin Invest. 1940. V. 19. P.649–657.
- Bannon A.W., Malmberg A.B. // Curr Protoc Neurosci. 2007. Chapter 8:Unit 8.9.
- Douglas D.K. and Carstens E. // J Neurophysiol. 1997. V. 77. P. 611–620.
- Maisonpierre P.C., Belluscio L., Friedman B., et al. // Neuron. 1990. V. 5. P. 501–509.
- Ernfors P., Rosario C.M., Merlio J.P., et al. // Brain Res. Mol. Brain Res. 1993. V.17. P. 217–226.
- Гудашева Т.А., Константинопольский М.А., Тарасюк А.В., и др. // ДАН. 2019. Т. 485. № 3. С. 366–369.
- Helgren M.E, Cliffer K.D., Torrento K., et al. // J. Neurosci. 1997. V. 17. P. 372–382.
- Sahenk Z., Nagaraja H.N., McCracken B.S., et al. // Neurology. 2005. V. 65. P. 681–689.
- Степанова О.В., Воронова А.Д., Чадин А.В., и др. // Клеточные технологии в биологии и медицине. 2022. Т. 1. С. 3–8.
Supplementary files
